Yanliang Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yanliang Yu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Chuanzhong Yang
Department of Neonatology, Shenzhen Maternity and Child Healthcare Hospital, The First School of Clinical Medicine, Southern Medical University, Shenzhen, China
2 shared publications - Bingchun Lin
Department of Neonatology and Neonatal Intensive Care Unit, Affiliated Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, Shenzhen 518028, China
1 shared publication - Bingchun Lin
Department of Neonatology, Affiliated Shenzhen Maternity & Child Healthcare Hospital, Southern Medical University, Shenzhen, Guangdong Province, China
1 shared publication - Haifeng Zong
Department of Neonatology and Neonatal Intensive Care Unit, Affiliated Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, Shenzhen 518028, China
1 shared publication - Hongyan Sun
Neonatal Intensive Care Unit, Shenzhen Maternity and Child Healthcare Hospital, Women and Children’s Medical Center, Southern Medical University, Shenzhen 518028, China
1 shared publication - Jie Zhao
Department of Neonatology and Neonatal Intensive Care Unit, Affiliated Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, Shenzhen 518028, China
1 shared publication
Latest Publications
- Open Access
- 25 July 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (30) , e42046
Continuous renal replacement therapy in a neonate with methylmalonic acidemia and severe hyperammonemia: A case report
Background: Methylmalonic acidemia (MMA) is a rare disease that is often misdiagnosed and overlooked. Metabolic acidosis and severe hyperammonemia are severe morbidities of MMA that demand immediate treatment. Case-diagnosis: Here, we describe an MMA neonate with severe hyperammonemia and acidosis that was successfully rescued by continuous renal replacement therapy. A 6-day-old male neonate, with a gestational age of 39 + 3 weeks and a birth weight of 2880 g, was admitted to the emergency with the symptoms of “cyanosis of the face and coma for 2 hours.” The infant was suffering from hypoglycemia, hypocalcemia, severe hyperammonemia, and severe metabolic acidosis. After admission, the blood ammonia continued to rise, and continuous renal replacement therapy was promptly administered until the patient gradually regained consciousness. Blood tandem mass spectrometry and profiles revealed that methylmalonic acid and methyl citrate levels were significantly enhanced. Two heterozygous mutations were detected in the MUT gene, confirming the diagnosis of methylmalonic acidemia mut. Conclusions: The patient’s symptoms gradually improved after receiving vitamin B12, l-carnitine, and specialized milk feeding. The patient was successfully discharged from the hospital after 41 days.
- 25 July 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (30) , e42046
Open AccessContinuous renal replacement therapy in a neonate with methylmalonic acidemia and severe hyperammonemia: A case report
Background: Methylmalonic acidemia (MMA) is a rare disease that is often misdiagnosed and overlooked. Metabolic acidosis and severe hyperammonemia are severe morbidities of MMA that demand immediate treatment. Case-diagnosis: Here, we describe an MMA neonate with severe hyperammonemia and acidosis that was successfully rescued by continuous renal replacement therapy. A 6-day-old male neonate, with a gestational age of 39 + 3 weeks and a birth weight of 2880 g, was admitted to the emergency with the symptoms of “cyanosis of the face and coma for 2 hours.” The infant was suffering from hypoglycemia, hypocalcemia, severe hyperammonemia, and severe metabolic acidosis. After admission, the blood ammonia continued to rise, and continuous renal replacement therapy was promptly administered until the patient gradually regained consciousness. Blood tandem mass spectrometry and profiles revealed that methylmalonic acid and methyl citrate levels were significantly enhanced. Two heterozygous mutations were detected in the MUT gene, confirming the diagnosis of methylmalonic acidemia mut. Conclusions: The patient’s symptoms gradually improved after receiving vitamin B12, l-carnitine, and specialized milk feeding. The patient was successfully discharged from the hospital after 41 days.
- Open Access
- 4 July 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (13) , 2263
The Predictive Value of Lung Ultrasound Score on Hemodynamically Significant Patent Ductus Arteriosus among Neonates ≤25 Weeks
Lung ultrasound (LU) is increasingly used to diagnose and monitor neonatal pulmonary disorders; however, its role in hemodynamically significant patent ductus arteriosus (hsPDA) has not been elucidated. This prospective study investigated the predictive value of the LU score (LUS) for hsPDA in preterm infants with gestational age (GA) ≤ 25 weeks. Preterm infants with GA ≤ 25 weeks were enrolled in this study. LU was conducted on the fourth day of life (DOL). Six lung regions in every lung were scanned, with each region rated as 0–4 points. The performance of the LUS in predicting hsPDA among infants aged ≤25 weeks was analyzed by plotting the receiver operating characteristic (ROC) curve. A total of 81 infants were included in this study. GA, birth weight (BW), gender, Apgar score, delivery mode, antenatal steroids, meconium-stained amniotic fluid, premature rapture of membrane, and early-onset sepsis were not significantly different, but infants in the hsPDA group had increased LUS (38.2 ± 2.8 vs. 30.3 ± 4.3, p < 0.001) compared with non-hsPDA group. The area under the ROC curve (AUC) value of the LUS on the fourth DOL was 0.94 (95% CI: 0.93–0.99) in predicting hsPDA. The LUS threshold at 33 achieved 89% sensitivity and 83% specificity, with the positive and negative predictive values (PPV and NPV) being 87 and 86%, respectively. The LUS can predict hsPDA in extremely preterm infants at an early stage.
- 4 July 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (13) , 2263
Open AccessThe Predictive Value of Lung Ultrasound Score on Hemodynamically Significant Patent Ductus Arteriosus among Neonates ≤25 Weeks
Lung ultrasound (LU) is increasingly used to diagnose and monitor neonatal pulmonary disorders; however, its role in hemodynamically significant patent ductus arteriosus (hsPDA) has not been elucidated. This prospective study investigated the predictive value of the LU score (LUS) for hsPDA in preterm infants with gestational age (GA) ≤ 25 weeks. Preterm infants with GA ≤ 25 weeks were enrolled in this study. LU was conducted on the fourth day of life (DOL). Six lung regions in every lung were scanned, with each region rated as 0–4 points. The performance of the LUS in predicting hsPDA among infants aged ≤25 weeks was analyzed by plotting the receiver operating characteristic (ROC) curve. A total of 81 infants were included in this study. GA, birth weight (BW), gender, Apgar score, delivery mode, antenatal steroids, meconium-stained amniotic fluid, premature rapture of membrane, and early-onset sepsis were not significantly different, but infants in the hsPDA group had increased LUS (38.2 ± 2.8 vs. 30.3 ± 4.3, p < 0.001) compared with non-hsPDA group. The area under the ROC curve (AUC) value of the LUS on the fourth DOL was 0.94 (95% CI: 0.93–0.99) in predicting hsPDA. The LUS threshold at 33 achieved 89% sensitivity and 83% specificity, with the positive and negative predictive values (PPV and NPV) being 87 and 86%, respectively. The LUS can predict hsPDA in extremely preterm infants at an early stage.